News Search Results
Apr 23, 2026, 03:00 ET MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
with follicular lymphoma respond well to initial treatment and patients' prognosis has improved, around one in five will see their lymphoma return within two years, which is often linked to poorer long-term outcomes," said Professor Judith Trotman, Senior Staff Specialist and Lymphoma Group Lead in the
More news about: Specialised Therapeutics
Apr 21, 2026, 21:26 ET 【2026 ASCO】亞盛醫藥多項研究入選，其中三項獲快速口頭報告
open-label, randomized, phase 3 registrational study of Lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress利沙托克拉（APG-2575）治療既往經治慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者的全球
More news about: 亞盛醫藥
Apr 21, 2026, 19:30 ET ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
principal investigator of the study.VT-EBV-N is an Epstein-Barr virus (EBV)-specific T cell therapy being developed for the treatment of NK/T-cell lymphoma, a rare and aggressive malignancy with a high risk of relapse.According to the company, the Phase 2 study demonstrated clinically meaningful
More news about: ViGenCell Inc.
Apr 21, 2026, 12:45 ET Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
without known driver mutations. Golidocitinib is the world's first and only approved JAK1 inhibitor for relapsed or refractory peripheral T-cell lymphoma. Preclinical data indicate that JAK inhibition can rescue exhausted T-cell function and modulate the tumor microenvironment, providing a mechanistic
More news about: Dizal Pharmaceutical
Apr 21, 2026, 12:03 ET Verismo Therapeutics Presents Preclinical Data at AACR 2026 for SynKIR™-310 KIR-CAR Indicating Superior Preclinical Activity in B Cell Malignancies and Early Clinical Efficacy
follicular lymphoma who received SynKIR™-310 KIR-CAR at the lowest dose level (DL1) and achieved complete tumor response 28 days later, which remains ongoing as of their most recent 6-month follow-up appointment.The CELESTIAL-301 trial is supported in part by the Institute for Follicular Lymphoma Innovation
More news about: Verismo Therapeutics
Apr 21, 2026, 10:32 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.
Apr 21, 2026, 08:00 ET Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
therapy. Most of the patients were receiving concomitant immunosuppressants.Post-marketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease
More news about: Celltrion
Apr 20, 2026, 10:51 ET St. David's South Austin Medical Center first in world to enroll patient in clinical trial evaluating a next-generation treatment for aggressive large B-cell lymphoma
cancerous B-cells in patients with aggressive large B-cell lymphoma receiving treatment in the second-line setting. "This study represents an important step forward in how we treat relapsed or resistant large B-cell lymphoma," Uttam Rao, M.D., principal investigator for the study
More news about: St. David's South Austin Medical Center
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data were presented in an oral session delivered at the AACR Annual Meeting 2026 in San Diego by Professor Li Wang of Ruijin Hospital
More news about: Abogen
Apr 20, 2026, 10:00 ET AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data were presented in an oral session delivered at the AACR Annual Meeting 2026 in San Diego by Professor Li Wang of Ruijin Hospital
More news about: Abogen
Apr 19, 2026, 20:48 ET 【直擊AACR 2026】亞盛醫藥公布四項臨床前進展，展現多重聯合治療潛力
信號通路，誘導DNA損傷，並進一步促進腫瘤的細胞凋亡。上述研究結果，為後續開展探索奧雷巴替尼單藥及與其他獲批療法聯合治療EC患者的臨床試驗提供了重要依據。（摘要編號：5875）Multikinase inhibitor Olverembatinib (HQP1351) is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma (MCL) preclinical models多激酶抑制劑奧雷巴替尼（HQP1351）在套細胞淋巴瘤（MCL）臨床前模型中具有抗腫瘤療效，並與BTK抑制劑阿可替尼存在協同作用背景介紹：
More news about: 亞盛醫藥
Apr 17, 2026, 09:00 ET Parker Institute for Cancer Immunotherapy Network Shapes the Future Of Immunotherapy with Latest Research at AACR Annual Meeting 2026
Abstract 4291)Michael Milone, MD, PhD (UPenn): Novel SynKIR-310 platform outperforming CD3-based CAR T in lymphoma models (
More news about: Parker Institute for Cancer Immunotherapy
Apr 15, 2026, 23:32 ET Global First | NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
models.As a key technological approach for directly mobilizing T cells to kill tumors, TCE has shown significant clinical value in various lymphoma indications, with multiple products successfully launched. However, current treatments for AML and CMML primarily remain primarily limited to chemotherapy,
More news about: Mabwell
Apr 15, 2026, 12:55 ET Florida Cancer Specialists & Research Institute Highlights Leadership in Advancing Medically Integrated Oncology Care
manager of real-world evidence and Christian Okitondo, biostatistician of real-world evidence—Real-world Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treatment Patterns at Florida Cancer Specialists & Research Institute Among Patients Receiving Zanubrutinib Immediately Following Prior BTKi Therapy
More news about: Florida Cancer Specialists & Research Institute
Apr 15, 2026, 10:16 ET America's Most Beautiful Bike Ride Unites Cyclists Against Blood Cancer in Lake Tahoe
breathtaking scenery, an unforgettable challenge, and a powerful call to action, Every pedal supports Blood Cancer United (formerly The Leukemia & Lymphoma Society). Funds raised advance the organization's mission to cure blood cancer and improve the quality of life of all patients and their families.
More news about: BLOOD CANCER UNITED, INC.
Apr 15, 2026, 08:00 ET Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development
Investment supports continued Phase 1 clinical advancement of SynKIR™-110 in advanced solid tumors and SynKIR™-310 in B cell non-Hodgkin lymphomaInitial clinical data from STAR-101 Phase 1 trial of SynKIR™-110 to be presented at AACR 2026 Late-Breaking Clinical
More news about: Verismo Therapeutics
Apr 15, 2026, 08:00 ET Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Apr 14, 2026, 08:50 ET Erin Lichy Gets Real About Her Natrelle® Breast Augmentation
surgery. Breast implants have been associated with the development of a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined.
More news about: AbbVie
Apr 13, 2026, 17:05 ET Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S.
More news about: Kazia Therapeutics Limited
Apr 13, 2026, 15:00 ET BioOra and Cincinnati Children's Hospital Medical Center Partner to Advance Next-Generation CAR-T Therapy for Children with Leukaemia
the tolerability profile compared with earlier-generation approaches. Results from the Phase 1 ENABLE-1 study in adults with relapsed or refractory lymphoma, presented at the
More news about: BioOra
Apr 13, 2026, 10:00 ET Communities Across the U.S. Unite in 10‑Week Challenge to Support Blood Cancer Patients
WASHINGTON, April 13, 2026 /PRNewswire/ -- Blood Cancer United, formerly The Leukemia & Lymphoma Society, has kicked off its 37th annual
More news about: BLOOD CANCER UNITED, INC.
Apr 13, 2026, 06:45 ET Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This
More news about: Eli Lilly and Company
Apr 10, 2026, 13:42 ET NAPT 2026 National Proton Conference Underscores Rapid Advances in Proton Therapy and Expanding Access Nationwide
incidence of 14 cancer types has risen among people under age 50, including breast, colorectal, kidney, uterine, pancreatic, testicular, and several lymphoma subtypes.
More news about: The National Association for Proton Therapy
Apr 07, 2026, 18:06 ET Ulrich Steidl, M.D., Ph.D., es nombrado director del Montefiore Einstein Comprehensive Cancer Center
reconocimientos del Dr. Steidl también destacan el Scholar Achievement Award otorgado por Blood Cancer United (conocida anteriormente como Leukemia & Lymphoma Society) en 2019; el Outstanding Investigator Award concedido por el NCI en 2021 y, hace tan solo un año, el McCulloch & Till Award, en 2025,
More news about: Montefiore Einstein Comprehensive Cancer Center
Apr 07, 2026, 14:43 ET Ulrich Steidl, M.D., Ph.D., Named Director of Montefiore Einstein Comprehensive Cancer Center
institutions worldwide.Dr. Steidl's additional honors include the Scholar Achievement Award from Blood Cancer United (formerly the Leukemia & Lymphoma Society) in 2019, the Outstanding Investigator Award from the NCI in 2021, and most recently, the 2025 McCulloch & Till Award from the International
More news about: Montefiore Einstein Comprehensive Cancer Center